Search results for "Neoplastic"

showing 10 items of 2901 documents

AR-V7 Protein Expression in Circulating Tumour Cells Is Not Predictive of Treatment Response in mCRPC

2019

<b><i>Introduction:</i></b> Androgen receptor variant 7 (AR-V7) plays an important role in the progression of castration-resistant prostate cancer (CRPC) and has shown potential as a predictive biomarker in circulating tumour cells (CTCs) isolated from the bloodstream in terms of a liquid biopsy. Studies have shown that AR-V7 is a potential surrogate for selecting drug classes for systemic treatment by detecting nuclear AR-V7 by immunofluorescence or measuring AR-V7 messenger RNA by quantitative PCR. Here, we assessed the predictive value of AR-V7 detected by classical immunohistochemistry (IHC) for treatment response. <b><i>Methods:</i></b> C…

MaleUrology030232 urology & nephrologyAntineoplastic AgentsDocetaxel03 medical and health scienceschemistry.chemical_compoundProstate cancer0302 clinical medicineCell Line TumormedicineHumansEnzalutamideProspective StudiesLiquid biopsyAgedAged 80 and overbusiness.industryAndrogen AntagonistsNeoplastic Cells CirculatingPrognosismedicine.diseaseAndrogen receptorProstatic Neoplasms Castration-ResistantTreatment OutcomeDocetaxelchemistryReceptors AndrogenCabazitaxel030220 oncology & carcinogenesisCancer researchBiomarker (medicine)ImmunohistochemistryTaxoidsbusinessmedicine.drugUrologia Internationalis
researchProduct

New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) fo…

2017

There has been considerable progress in treating malignant melanoma over the last few years. The immune-checkpoint-inhibitors nivolumab and pembrolizumab have been approved by the Food and Drug Administration in 2014 for the therapy of metastatic melanoma. Anti-programmed cell death-1-blocking antibodies are known to cause immune-related adverse events. Physicians should be aware of common and rare side effects and pay attention to new ones. We therefore report a severe and life-threatening side effect of anti-programmed cell death-1 immunotherapy with nivolumab that has not been previously reported: the development of a third-degree atrioventricular block. After a second infusion with nivo…

MaleUveal NeoplasmsOncologyCancer Researchmedicine.medical_specialtyMyocarditisSide effectDermatologyPembrolizumab030204 cardiovascular system & hematologyAutoimmune Diseases03 medical and health sciencesAntineoplastic Agents ImmunologicalFatal Outcome0302 clinical medicineInternal medicineHumansMedicineAtrioventricular BlockMelanomaMyositisMyositisbusiness.industryThird-degree atrioventricular blockMelanomaAntibodies MonoclonalMiddle Agedmedicine.diseaseNivolumabOncology030220 oncology & carcinogenesisImmunologyNivolumabbusinessAtrioventricular blockMelanoma Research
researchProduct

HIF-1α and HIF-2α Are Differentially Regulated In vivo in Neuroblastoma: High HIF-1α Correlates Negatively to Advanced Clinical Stage and Tumor Vascu…

2009

Abstract Purpose: Hypoxia is considered to be a major driving force behind tumor angiogenesis. The stabilization and activation at hypoxia of the hypoxia-inducible factors HIF-1α and HIF-2α and the concomitant induction of expression of vascular endothelial growth factor (VEGF) and other proangiogenic factors provide a molecular frame for hypoxia-driven tumor angiogenesis. This study has investigated how HIF and VEGF protein levels relate to each other with regard to vascularization, tumor stage, and overall survival in neuroblastoma. Experimental Design: Tissue cores taken from tumor specimens representing 93 children with neuroblastoma were arranged on a microarray and stained for HIF-1α,…

MaleVascular Endothelial Growth Factor ACD31Cancer ResearchPathologymedicine.medical_specialtyBiologyModels BiologicalNeovascularizationchemistry.chemical_compoundIn vivoNeoplasmsNeuroblastomaBasic Helix-Loop-Helix Transcription FactorsmedicineHumansHypoxiaRegulation of gene expressionNeovascularization PathologicInfantCancerHypoxia-Inducible Factor 1 alpha Subunitmedicine.diseaseGene Expression Regulation NeoplasticPlatelet Endothelial Cell Adhesion Molecule-1Vascular endothelial growth factorTreatment OutcomeHIF1AOncologychemistryChild PreschoolCancer researchFemalemedicine.symptomClinical Cancer Research
researchProduct

Lactate: mirror and motor of tumor malignancy

2004

A number of studies have shown that malignant transformation is associated with an increase in glycolytic flux and in anaerobic and aerobic cellular lactate excretion. Using quantitative bioluminescence imaging in various primary carcinomas in patients (uterine cervix, head and neck, colorectal region) at first diagnosis of the disease, we showed that lactate concentrations in tumors in vivo can be relatively low or extremely high (up to 40 micromol/g) in different individual tumors or within the same lesion. In all tumor entities investigated, high concentrations of lactate were correlated with a high incidence of distant metastasis already in an early stage of the disease. Low lactate tum…

MaleVascular Endothelial Growth Factor ACancer ResearchPathologymedicine.medical_specialtyMalignancyMalignant transformationchemistry.chemical_compoundNeoplasmsLactate dehydrogenasemedicineHumansBioluminescence imagingRadiology Nuclear Medicine and imagingGlycolysisLactic AcidHyaluronic AcidNeoplasm MetastasisL-Lactate Dehydrogenasebusiness.industryHypoxia-Inducible Factor 1 alpha Subunitmedicine.diseaseCell HypoxiaUp-RegulationVascular endothelial growth factorCell Transformation NeoplasticOncologychemistryCancer cellFemalebusinessAnaerobic exerciseTranscription FactorsSeminars in Radiation Oncology
researchProduct

Fungal polysaccharopeptide inhibits tumor angiogenesis and tumor growth in mice

2003

Angiogenesis is crucial to tumor growth and metastasis, and interruption of this process is a prime avenue for therapeutic intervention of tumor proliferation. The present study has made use of the S180 tumor-bearing mouse model to investigate the polysaccharopeptide, PSP, isolated from the edible mushroom Coriolus versicolor, a herbal medicine known for its anti-angiogenesis properties. Quantitative analysis of microcorrosion casting of the tumor tissue showed more angiogenic features such as dense sinusoids and hot spots, in control (untreated) than in PSP-treated animals. Immunostaining of tumor tissues with antibody against the endothelial cell marker (Factor VIII) demonstrated a positi…

MaleVascular Endothelial Growth Factor APathologymedicine.medical_specialtyAngiogenesisDrinkingAdministration OralBiologyCorrosion CastingGeneral Biochemistry Genetics and Molecular BiologyMetastasisNeovascularizationMiceImage Processing Computer-AssistedmedicineAnimalsRNA MessengerRNA NeoplasmGeneral Pharmacology Toxicology and PharmaceuticsFluorescent Antibody Technique IndirectMice Inbred BALB CNeovascularization PathologicReverse Transcriptase Polymerase Chain ReactionBasidiomycotaWaterGeneral Medicinemedicine.diseaseAntineoplastic Agents PhytogenicEndothelial stem cellDisease Models AnimalVascular endothelial growth factor AMicroscopy Electron Scanningbiology.proteinBlood VesselsProteoglycansSarcoma ExperimentalSarcomamedicine.symptomAntibodyNeoplasm TransplantationImmunostainingLife Sciences
researchProduct

Combination chemotherapy with cyclophosphamide, doxorubicin and vincristine in the treatment of stage III-IV small-cell lung cancer.

1989

SummaryTwenty patients with histologically confirmed small-cell lung cancer were treated with cyclophosphamide 1000 mg/m2 i.v. on day 1, vincristine 1.4 mg/m2 i.v. day 1, and adriamycin 50 mg/m2 i.v. on day 1. This protocol was repeated every 21 days. Out of 17 evaluable patients 2 obtained a complete response (12%) with a mean duration of 11 months, 4 patients achieved a partial response with a mean duration of 6.3 + months, and 1 had a minimal response of 7.2 months. Two patients had a stabilization which lasted a mean of 4 + months, while 8 patients progressed. Although the mean survival was higher in responders than in non-responders, the difference in survival time was not statisticall…

MaleVincristinemedicine.medical_specialtyLung NeoplasmsCyclophosphamideGastroenterologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)Stage (cooking)Carcinoma Small CellLung cancerCyclophosphamideAgedNeoplasm StagingPharmacologybusiness.industryNeurotoxicityCombination chemotherapyMiddle Agedmedicine.diseaseSurgerySurvival RateInfectious DiseasesOncologyCyclophosphamide/doxorubicinDoxorubicinVincristineFemaleNon small cellbusinessmedicine.drugFollow-Up StudiesJournal of chemotherapy (Florence, Italy)
researchProduct

Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxe…

2010

There is currently no standard of treatment for patients with hormone refractory prostate cancer (HRPC) after failure of docetaxel-based chemotherapy. The purpose of this study was to assess the anticancer activity and tolerance of metronomic cyclophosphamide prednisolone combination in this setting.From 2005 to 2010, patients with HRPC who failed at least docetaxel-based chemotherapy were proposed metronomic cyclophosphamide-prednisolone regimen, and were prospectively registered. Twenty-three patients received 50 mg cyclophosphamide and 10 mg prednisolone per os daily until disease progression. Treatment tolerance and efficacy on PSA decrease and pain were studied.Metronomic cyclophospham…

Male[SDV.IMM] Life Sciences [q-bio]/ImmunologyMESH : Antineoplastic Combined Chemotherapy ProtocolsMESH: Treatment FailurePrednisoloneMESH : MaleMESH : PrednisoloneMESH: TaxoidsMESH : AgedMESH : Prospective StudiesDocetaxelMESH : Treatment OutcomeMESH : Treatment FailureMESH: Aged 80 and overAntineoplastic Combined Chemotherapy ProtocolsHumans[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyMESH : Middle AgedProspective StudiesTreatment FailureMESH : Prostate-Specific AntigenMESH : Aged 80 and overMESH : TaxoidsCyclophosphamideMESH : Cyclophosphamidehealth care economics and organizationsAgedMESH: Treatment OutcomeAged 80 and overMESH: AgedMESH: HumansMESH: Middle AgedMESH : HumansProstatic NeoplasmsMESH: CyclophosphamideMiddle AgedProstate-Specific AntigenMESH: MaleMESH: Prospective StudiesMESH: Prostate-Specific AntigenMESH: Antineoplastic Combined Chemotherapy ProtocolsTreatment OutcomeMESH: Prostatic Neoplasms[SDV.IMM]Life Sciences [q-bio]/ImmunologyTaxoidsMESH: PrednisoloneMESH : Prostatic Neoplasms
researchProduct

Completion Surgery After Concomitant Chemoradiation in Locally Advanced Cervical Cancer: A Comprehensive Analysis of Pattern of Postoperative Complic…

2014

Background: We provided a comprehensive analysis of rate, pattern, and severity of early and late postoperative complications in a very large, single-institution series of locally advanced cervical cancer (LACC) patients administered CT/RT plus radical surgery (RS). Methods: A total of 362 consecutive LACC (FIGO stage IB2-IVA) patients were submitted to RS after CT/RT at the Gynecologic Oncology Unit of the Catholic University (Rome/Campobasso). At 4 weeks after CT/RT, patients were evaluated for objective response and triaged to radical hysterectomy and pelvic ± aortic lymphadenectomy. Surgical morbidity was classified according to the Chassagne's grading system. Results: Most cases underw…

Malecervical cancermedicine.medical_treatmentUterine Cervical NeoplasmsPostoperative ComplicationsAntineoplastic Combined Chemotherapy Protocols80 and overlocally advanced cervical cancerAdjuvantSettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIAAged 80 and overCervical cancerMedicine (all)Middle AgedPrognosisCombined Modality TherapyAdult; Aged; Aged; 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Squamous Cell; Chemotherapy; Adjuvant; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Humans; Hysterectomy; Lymph Node Excision; Male; Middle Aged; Neoplasm Grading; Postoperative Complications; Prognosis; Radiotherapy; Adjuvant; Survival Rate; Uterine Cervical Neoplasms; Young AdultSurvival RateOncologyChemotherapy AdjuvantCarcinoma Squamous CellFemaleFluorouracilAdultmedicine.medical_specialtyGynecologic oncologyHysterectomyYoung AdultmedicineHumansChemotherapyRadical HysterectomyRadical surgeryconcomitant chemoradiationSurvival rateAgedHysterectomyRadiotherapybusiness.industryCarcinomamedicine.diseaseSurgerySettore MED/40 - GINECOLOGIA E OSTETRICIASquamous CellConcomitantLymph Node ExcisionRadiotherapy AdjuvantSurgeryLymphadenectomyCisplatinNeoplasm GradingbusinessFollow-Up StudiesAnnals of Surgical Oncology
researchProduct

Hsp60 expression, new locations, functions and perspectives for cancer diagnosis and therapy.

2008

Hsp60 in eukaryotes is considered typically a mitochondrial chaperone (also called Cpn60) but in the last few years it has become clear that it also occurs in the cytosol, the cell surface, the extracellular space, and in the peripheral blood. Studies with prokaryotic models have shown that Hsp60 plays a role in assisting nascent polypeptides to reach a native conformation, and that it interacts with Hsp10 (which also resides in the mitochondria and is also named Cpn10). In addition to its role in polypeptide folding in association with Hsp10, other functions and interacting molecules have been identified for Hsp60 in the last several years. Some of these newly identified functions are asso…

MalechaperoninCancer ResearchProtein Foldinganimal structuresChaperoninsCell SurvivalCelldifferential diagnosiGene ExpressionAntineoplastic AgentsApoptosisBiologyMitochondrionmedicine.disease_causeBioinformaticsDiagnosis Differentialtumor-cell survivalCell Line TumorNeoplasmstumor diagnosiExtracellularmedicineHumansHsp60 (Cpn60)chaperonotherapyPharmacologyClinical Oncologymonitoring response to treatmentanti-tumor immune responsefungiHsp60 (Cpn60); tumor-cell survival; apoptosis; tumor diagnosis; differential diagnosis; assessing prognosis; monitoring response to treatment; chaperonotherapy; anti-tumor immune response; chaperonin; protein foldingassessing prognosiChaperonin 60PrognosisapoptosiCell biologyCytosolmedicine.anatomical_structureOncologyChaperone (protein)biology.proteinMolecular MedicineHSP60FemaleCarcinogenesisSignal TransductionCancer biologytherapy
researchProduct

Elevated AA/EPA Ratio Represents an Inflammatory Biomarker in Tumor Tissue of Metastatic Colorectal Cancer Patients

2019

Chronic inflammation increases the risk of developing certain types of cancer, such as colorectal cancer (CRC). The oxidative metabolism of polyunsaturated fatty acids (PUFAs) has a strong effect on colonic tumorigenesis and the levels of arachidonic acid (AA) and eicosapentaenoic acid (EPA) can contribute to the development of an inflammatory microenvironment. Aim of this study was to evaluate the possible differences in the AA/EPA ratio tissue levels between CRC patients with and without synchronous metastases. Moreover, the expression of the most important inflammatory enzymes and mediators, linked with the AA/EPA ratio, have been also assessed. Sixty-eight patients with CRC were enrolle…

Maleeicosapentaenoic acidColorectal cancermedicine.disease_causeMetastasislcsh:ChemistryReceptor Cannabinoid CB2chemistry.chemical_compoundMedicineArachidonate 15-LipoxygenaseNeoplasm Metastasislcsh:QH301-705.5Spectroscopychemistry.chemical_classificationGeneral MedicineEicosapentaenoic acidComputer Science ApplicationsGene Expression Regulation NeoplasticArachidonic acidArachidonic acidFemalelipids (amino acids peptides and proteins)medicine.symptomColorectal NeoplasmsPolyunsaturated fatty acidInflammationcolorectal cancerCatalysisArticleInorganic ChemistryBiomarkers TumorHumansmetastasisRNA MessengerPhysical and Theoretical ChemistryMolecular BiologyAgedInflammationbusiness.industryOrganic Chemistryinflammatory biomarkerCancermedicine.diseasePPAR gammalcsh:Biology (General)lcsh:QD1-999chemistryCancer researchbusinessCarcinogenesisInternational Journal of Molecular Sciences
researchProduct